Erin Yoder

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer

Yuan Yuan, Jin Sun Lee, Susan E. Yost et al. · The Oncologist · 2020 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

Estrogen receptor variants in ER-positive basal-type breast cancers responding to therapy like ER-negative breast cancers

Floris H. Groenendijk, Tina Treece, Erin Yoder et al. · npj Breast Cancer · 2019 · 28 citations · Full text

Medicine, Cancer Biology, Oncology +17

Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature

Pat W. Whitworth, Peter D. Beitsch, James Pellicane et al. · JCO Precision Oncology · 2022 · 18 citations · Full text

Medicine, Oncology, Breast Oncology +15

Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer

Pat W. Whitworth, Peter D. Beitsch, James Pellicane et al. · Annals of Surgical Oncology · 2022 · 15 citations · Full text

Medicine, Oncology, Breast Oncology +14

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

Peter D. Beitsch, Pat W. Whitworth, Paul L. Baron et al. · Annals of Surgical Oncology · 2016 · 14 citations

Medicine, Genetics, Oncology +17